Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 7, 2024CNS DrugsOpen Access

Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAmira SalimEHElise HennessyCSClaire Sonneborn

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Salim et al. (2024) studied this question.

synapsesocial.com/papers/68e701efb6db64358767b98ahttps://doi.org/10.1007/s40263-024-01086-z
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dual-mechanism preventive therapy in chronic migraine: an exploratory meta-analysis of onabotulinumtoxinA and anti-CGRP monoclonal antibody combination2026
  2. 2Real-world effectiveness of onabotulinumtoxinA as first-line treatment in chronic migraine and sequential transition to anti-CGRP monoclonal antibodies: a retrospective multicenter study.2026
  3. 3Anti-CGRP monoclonal antibodies for chronic migraine with medication-overuse headache: a conservative meta-analysis2026 · 1 citations
  4. 4Comparative effectiveness and tolerability of calcitonin gene‐related peptide (<scp>CGRP)</scp> monoclonal antibodies and <scp>onabotulinumtoxinA</scp> in chronic migraine: A multicenter, real‐world study in Taiwan2024 · 3 citations
  5. 5PO-91 | Real-world evidence of CGRP dual blockade: clinical and biomarker insights from combined therapy in chronic migraine2025